iPSC TCR Integration at EEF1A1 Locus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current autologous T-cell therapies for cancer treatment are complex and time-consuming, with allogeneic approaches facing challenges in producing clonal T-cell populations with stable heterologous T-cell receptor expression due to inefficient lentiviral transduction and promoter silencing, complicating the prevention of endogenous TCR expression.
Innovation Solution
Targeted insertion of a recombinant heterologous T-cell receptor sequence into a locus in induced pluripotent stem cells (iPSCs) using a minimal editing strategy, such as integration into the eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) gene, to achieve consistent and stable expression in differentiated iT-cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lentiviral transduction is used to express heterologous TCR in hiPSC, then TCR expression can be achieved, but promoter silencing occurs and transgene expression becomes unstable
Solution Approach 1:
The patent extracts the heterologous TCR coding sequence from the lentiviral vector system and integrates it directly into the iPSC genome at a specific locus (EEF1A1 gene). This removes the reliance on viral promoters that cause silencing, achieving stable long-term expression without the harmful effects of promoter silencing associated with lentiviral transduction.
Solution Approach 2:
The patent performs preliminary genome editing to create a targeted integration site at the EEF1A1 locus before TCR expression is required. By pre-establishing the correct genomic context and using homology-directed repair with a donor template containing the TCR sequence, the system ensures stable integration and expression from the outset, avoiding subsequent promoter silencing issues.
2Reliability
If autologous T-cell therapy is used, then patient-specific T-cells can be generated, but manufacturing complexity and time increase
Solution Approach 1:
The patent creates a standardized platform using induced pluripotent stem cells that can be differentiated into T-cells with engineered heterologous TCRs. Instead of processing each patient's own lymphocytes through complex procedures, the system uses a reproducible cell model that can be manufactured off-the-shelf, significantly reducing manufacturing complexity while maintaining patient-specific treatment capability through customization of the TCR sequence.
Solution Approach 2:
The patent changes the fundamental approach from processing patient lymphocytes to programming stem cells. By altering the cellular starting material and using genome editing technologies, the system transforms a complex, time-consuming process into a more efficient, standardized manufacturing process that can produce patient-specific T-cells with engineered receptors.
3Loss of time
If allogeneic T-cell therapy is used, then treatment time is reduced, but producing clonal T-cell populations with stable heterologous TCR expression becomes difficult
Solution Approach 1:
The patent applies local quality by targeting a specific genomic locus (EEF1A1) for integration rather than using random integration or multiple genes. This localized approach ensures that the heterologous TCR is expressed from a defined position in the genome, creating a clonal population with consistent, stable expression. The specificity of the target locus provides manufacturing precision that enables reliable production of clonal T-cell populations for allogeneic therapy.
4Reliability
If endogenous TCR expression is prevented in differentiated iT-cells, then heterologous TCR expression can be stabilized, but multiple genes must be inactivated which complicates the process
Solution Approach 1:
The patent converts the potential harm of endogenous TCR expression into a benefit by using the EEF1A1 gene as a target for integration. Instead of trying to silence multiple endogenous TCR genes, the system leverages the EEF1A1 locus as a safe harbor that provides constitutive expression. The heterologous TCR is integrated into this actively transcribed gene, ensuring stable expression without needing to inactivate other genes, thus turning a complex multi-gene editing problem into a single locus integration solution.
Data Source
AI summary
The present invention provides a modified iPSC or haemogenic lineage cell, such as a T cell, comprising at least one heterologous nucleic acid sequence encoding a heterologous T-cell receptor (TCR) integrated in the cell genome, for example in the eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) gene and uses thereof.